Barclays analyst Michael Leithead lowered the firm’s price target on Chemours to $28 from $31 and keeps an Equal Weight rating on the shares. The analyst updated the company’s model post the Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CC:
